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The role of hyper-gastrinaemia in the incidence of colonic cancer remains to be clariﬁed. The aim of this study was to
determine whether cholecystokinin-2 (CCK-2) receptor expression predicts the sensitivity of human colonic adenomas to the
proliferative effects of serum hyper-gastrinaemia. Gene expression of the classical (74 kDa) CCK-2 receptor in human colonic
adenoma specimens and cell lines, was quantiﬁed by real-time PCR. Western blotting, using a CCK-2 receptor antiserum,
conﬁrmed protein expression. A transformed human colonic adenoma was grown in SCID mice, with hyper-gastrinaemia
induced by protein pump inhibitors. CCK-2 receptor blockade was achieved by using neutralising antiserum. Both human
colonic adenoma cell lines and biopsies expressed CCK-2 receptor mRNA at levels comparable with CCK-2 receptor
transfected ﬁbroblasts and oxyntic mucosa. Western blotting conﬁrmed immunoreactive CCK-2 receptor bands localised to
45, 74 and 82.5 kDa. Omeprazole and lansoprazole-induced hyper-gastrinaemia (resulting in serum gastrin levels of 34.0 and
153.0 pM, respectively) signiﬁcantly increased the weight of the human adenoma grafts (43% (P=0.016) and 70% (P=0.014),
respectively). The effect of hypergastrinaemia on tumour growth was reversed by use of antiserum directed against the CCK-2
receptor. Hyper-gastrinaemia may promote proliferation of human colonic adenomas that express CCK-2 receptor isoforms.
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Gastrin peptides have been shown to be growth factors for normal
colonic epithelial cells (Sobhani et al, 1993; Koh et al, 1997; Renga
et al, 1997), as well as those that have undergone malignant transfor-
mation (Winsett et al, 1986; Watson et al, 1989). Such ﬁndings may
be of clinical signiﬁcance as raised serum gastrin levels may be a
common occurrence, being a side effect following either infection
with Helicobacter pylori (HP) (Smith et al, 1990; Graham et al,
1991) or administration of proton pump inhibitors (Festen et al,
1986; Lind et al, 1988). The ability of elevated serum gastrin levels
to promote colorectal carcinogenesis has been evaluated in a number
of chemically induced in vivo models. Omeprazole-induced hyper-
gastrinaemia has consistently failed to increase tumour incidence in
carcinogen-induced colorectal malignancy in rats (Penman et al,
1993; Hurwitz et al, 1995; Pinson et al, 1995). Conversely, surgical
induction of hyper-gastrinaemia has resulted in an increased inci-
dence of chemically-induced tumours in two studies (McGregor et
al, 1982, Karlin et al, 1985). Furthermore, hyper-gastrinaemia
decreased survival in the APC
Min mouse model of intestinal polyposis
(Watson and Smith, 2001). The reasons for such divergent results are
unclear but they highlight the need to examine the risk of hyper-
gastrinaemia in more clinically relevant models.
The majority of epidemiological studies have so far failed to
deﬁne the true risk of hyper-gastrinaemia as most have not
controlled for confounding factors, known to elevate serum gastrin,
in the control population (Elsborg and Mosbech, 1979; Brinton et
al, 1989; Orbuch et al, 1996). A well-controlled clinical study by
Thorburn et al (1998) showed that serum hyper-gastrinaemia was
associated with a 3.3-fold increase in the relative risk of developing
colorectal cancer with 8.9% of colorectal cancers attributable to
increased serum gastrin levels.
The cholecystokinin-B (CCK-2) receptor mediates the physiolo-
gical effects of gastrin, including growth promoting effects on pre-
malignant and malignant colonic mucosa (Smith and Watson,
2000). Furthermore, gastrin stimulation of CCK-2 receptors
expressed by AR42J cells was shown in an in vitro system to reverse
apoptosis induced by serum withdrawal through the induction/
activation of protein kinase BAkt (Todisco et al, 2001). A number
of isoforms of the CCK-2 receptor have now been discovered
(Song et al, 1993; Miyake, 1995; Ohtaki et al, 1996). These include
the ‘long isoform’ which has, due to alternate splicing, an addi-
tional ﬁve amino acids located within the third intracellular
domain (Song et al, 1993; Ohtaki et al, 1996). Use of an alternative
ﬁrst exon, 1b, which remains untranslated, leads to a receptor trun-
cated at the amino-terminus, known as the DCCK-2. This receptor
exists on human colorectal adenocarcinoma specimens and cell
lines which have an activated gastrin gene, and therefore has been
implicated in mediating the autocrine pathway (McWilliams et al,
1998). More recently, CCK-2 receptors with retained introns 2 and
4 have been described in malignant pancreatic and colorectal cells,
respectively (Goetze et al, 2000, Hellmich et al, 2000) with the
intron 4 retaining CCK-2 receptor inducing ligand-independent
constitutive intra-cellular Ca
2+ mobilisation (Hellmich et al,
2000). However their relevance regarding colonic tumour prolifera-
tion progression remains to be clariﬁed.
As the classical CCK-2 receptor mediates the proliferative
response to endocrine gastrin, the aim of the present study was
to deﬁne the signiﬁcance of non-truncated CCK-2 receptor
isoforms expressed by human colorectal adenomas.
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Human colonic adenoma cell lines
Three human adenoma cell lines were examined in this study; AA/
C1 and RGC2/42 are non-tumorigenic adenoma cell lines and AA/
C1/SB/10C is a semi-transformed variant of AA/C1 with limited in
vivo tumorigenic potential (Williams et al, 1990). A table of known
mutations is shown in Table 1. These cells were kindly provided by
Professor C Parasceva, CRC Laboratories, University of Bristol, UK.
The cell lines were maintained at 378C in humidiﬁed conditions
with 5% CO2, in conditioned medium from mouse NIH3T3 ﬁbro-
blasts prepared in DMEM tissue culture medium (GIBCO, Irvine,
Scotland) containing 20% heat-inactivated foetal calf serum (FCS,
Sigma, Poole, UK), 2 mML -glutamine (Sigma), insulin (0.2 Units
ml
71, Sigma) and hydrocortisone (1 mgm l
71, Sigma).
The human colorectal adenocarcinoma cells used were LoVo
and HT29, both obtained from the ECACC (Porton Down, UK),
and the human liver-invasive colorectal adenocarcinoma,
C170HM2, established within the Cancer Studies Unit, University
of Nottingham, UK (Watson et al, 1993). The CCK-2 receptor
transfected NIH3T3 cells were a kind gift from Professor Matsui,
Kobe University, Japan, as previously described (Ito et al, 1993).
All the above cell lines were maintained in RPMI tissue culture
medium supplemented with 10% FCS and 2 mML -glutamine.
Growth in severe combined immuno-deﬁcient (SCID) mice
AA/C1/SB/10C cells were injected subcutaneously (s.c.) into the left
ﬂank of mixed sex SCID mice (age 4–5 weeks, bred within the
Cancer Studies Unit, University of Nottingham, UK) at a cell
concentration of 2610
6 in 100 ml. After growth of a palpable
tumour (approximately 3 months), tumour tissue was pooled from
donor mice and 3 mm
3 grafts transplanted s.c. into experimental
SCID mice anaesthetised with Hypnorm (0.315 ng ml
71, Jannsen,
Belgium) and Hypnovel (5 ng ml
71, Roche, Switzerland). Tumour
grafts were measured as previously described (Watson et al, 1993).
One hour before study termination, mice were injected with
10 mg kg
71 bromodeoxyuridine (BrdU) into the peritoneal cavity.
At the termination of the study, tumour tissue was taken and ﬁxed
in formal calcium (4% formaldehyde, 10% CaCl2 in distilled water)
for immunohistological evaluation. Tumour tissue was snap-frozen
in liquid N2 for molecular biology studies. UK Co-ordinating
Committee for Cancer Research (UKCCCR) Guidelines were
adhered to throughout all animal experimentation.
In vivo treatment
Omeprazole (Hospital Pharmacy, Queen’s Medical Centre,
Nottingham, UK) was administered at a dose of 75 mg kg
71 by
gavage as previously described (Watson and Smith, 2001). Lanso-
prazole (Hospital Pharmacy as above) was prepared in sterile
distilled H2O and administered orally, daily, in 100 ml volumes at
a dose of 25 mg kg
71.
Afﬁnity puriﬁed polyclonal CCK-2 receptor (gastrin receptor
epitope (GRE)-1, Watson et al, 1998) antiserum (Aphton Corpora-
tion, CA, USA) was administered at a dose of 100 mg protein in a
200 ml volume, i.v., daily. This antiserum has been shown to inhibit
ligand binding and intra-cellular signalling of the CCK-2 receptor
(Watson et al, 2000; McWilliams et al, 2001). Protein G puriﬁed
normal rabbit serum (Aphton, CA, USA), at the same protein
concentration, was administered to control mice.
Amidated serum gastrin levels were measured by Professor Andrea
Varro (Physiology Department, University of Liverpool) using the L2
antiserum, as previously described (Nemeth et al, 1993).
Measurement of the proliferation index of the adenoma
tissue
Following formalin ﬁxation, specimens were embedded in parafﬁn,
4 mM sections were cut by a microtome and stained with an anti-
body directed against BrdU as previously described (Watson and
Smith, 2001). Nuclei were selected on the basis of colour and were
expressed as a percentage of the total adenoma tissue in n=20 high
power ﬁelds. Inter-observer variation was found to be 7.5% and
intra-observer variation 8.8%. Image analysis was performed by
the use of the Leica Qwin image processing system (Leica Micro-
systems, Cambridge, UK).
Human specimens
Either parafﬁn-embedded or snap frozen human colonic normal
mucosa (from patients without a malignancy), mucosa from the
resection margin of patients with an adenocarcinoma and villous
adenoma and adenocarcinoma specimens were used for the real-
time screen of CCK-2 receptor expression.
For the Western blotting studies, snap frozen tissue was
obtained from resection margin mucosa samples, villous adenomas
and adenocarcinomas, prospectively. The adenomas were mainly
synchronous to adenocarcinomas. Real-time PCR was performed
on respective samples, in parallel.
Extraction of RNA
For frozen and parafﬁn-embedded tissue, total RNA was extracted
as previously described (McWilliams et al, 1998; Smith and
Watson, 2000) and reverse transcription performed (McWilliams
et al, 1998).
Primer pairs, for use in real time PCR, were designed to amplify
only the human classical CCK-2 receptor. The sequences are shown
in Table 2.
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Table 1 Genetic characterisation of the colonic adenoma cell lines
Cell line Characterisation of oncogenic events
RGC2 Full length APC, c-myc but no k-ras mutation
AA/C1 Truncated APC, c-myc and k-ras mutation
AA/C1/SB/10C Truncated APC, c-myc and k-ras mutation
Table 2 PCR Primer Sequences
Primer Gene U/L Sequence
GAPU GAPDH (both species) U GGTGAAGGTCGGAGTCAACGGA
GAPL GAPDH (both species) L GAGGGATCTCGCTCCTGGAAGA
HCC1 Human Classical CCK-2 receptor U GCCAGACCTGGTCCGTACT
HCC2 Human Classical CCK-2 receptor L TCACTGTCGCCGTCAAAG
I4A Human Intron 4 retained CCK-2 receptor U TGGACCACGTGAGCAAAATC
I4B Human Intron 4 retained CCK-2 receptor L TCTCACCCTCACCTTCATTTCA
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RNA was reverse transcribed from random hexamer primers (Phar-
macia) using Superscript RT (GibcoBrl, UK). Real Time PCR was
performed using the 5700 Sequence Detection System (PE Applied
Biosystems, Warrington, UK). Each PCR was performed according
to manufacturer’s instructions using 1 ml of sample complementary
DNA (cDNA) in a 25 ml reaction volume. The reaction buffer was
prepared from the SYBR Green PCR Core Kit (PE Applied Biosys-
tems) and consisted of 16SYBR Green PCR Buffer (PE Applied
Biosystems), 3 mM MgCl2, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM
dGTP, 0.4 mM dUTP, 0.25 U AmpErase UNG (PE Applied Biosys-
tems) and 0.625 U Amplitaq Gold (PE Applied Biosystems). The
CCK-2 receptor primers and the primers for the house-keeping
gene, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) were
included in parallel reactions at a ﬁnal concentration of 100 nM
each. Negative controls were included in which the reverse tran-
scriptase was omitted, to control for genomic DNA contamination.
The ﬂuorescence of the SYBR green dye bound to the CCK-2
receptor and GAPDH PCR products was measured, after each
cycle, by the 5700 System and the cycle number was recorded when
the accumulated signal crossed an arbitrary cycle threshold (Ct).
The relative gene expression for each sample was determined using
the formula 2
ct(GAPDH)7ct(CCK72), in which CCK-2 receptor gene
expression was normalised to GAPDH levels. CCK-2 receptor
mRNA levels of the human adenoma xenografts were measured
by the ELOCA assay, as previously described (Watson et al,
1999a). Each sample (n=5) was repeated 2–3 times.
Western blotting
Western blotting was performed on cell pellets or human tissue,
snap frozen in liquid nitrogen, using a rabbit polyclonal antiserum
directed against the amino terminus of the classical human CCK-2
receptor, as previously described (Watson et al, 1998).
Statistical analysis
Results were assessed using the Minitab statistical programme for
the PC by the Mann–Whitney U non-parametric test (real time
PCR results) and the in vivo data by Student’s t-test or one-way
analysis of variance.
RESULTS
Real time CCK-2 receptor proﬁle of colonic adenoma and
adenocarcinoma cell lines
The mean DDCt (relative gene expression of CCK-2 receptor normal-
ised to GAPDH) of each cell line examined (means of 2–3 repeat
PCR reactions performed on two separate cDNA preparations) is
shown in Figure 1. The positive control cells used were NIH3T3s
transfected with the human classical CCK-2 receptor and the negative
control was the human ﬁbroblast cell line BRIG1, which showed no
receptor expression at the detection sensitivity of the real time PCR
assay (DDCt51610
712 in ﬁve repeated assays, results not shown).
The three human adenoma cell lines expressed classical CCK-2
receptor mRNA. The DDCt levels of CCK-2 receptor mRNA in
the two non-transformed adenoma cell lines were signiﬁcantly
greater when compared to the transformed adenoma, AA/C1/5B/
10C (P=0.0014, AA/C1 and P=0.0081, RGC2/42, Mann–Whitney).
The DDCt levels for the receptor were also higher in AA/C1 and
RGC2/42 cells when compared to the adenocarcinoma cell lines
(P=0.0008, P=0.0032 respectively). However, CCK-2 receptor DDCt
levels of the two non-transformed adenomas were not signiﬁcantly
different from those expressed by the NIH3T3 CCK-2 receptor
transfectants and were lower than the levels expressed by oxyntic
mucosa (P=0.0108, for AA/C1 and P=0.0081 for RGC2/42). When
comparing the adenocarcinoma cell lines, there was no signiﬁcant
difference in DDCt for the classical CCK-2 receptor between all
three lines, however, the DDCt values were lower than the level
expressed by the NIH3T3 receptor transfectant (P=0.0107), and
oxyntic mucosa (P=0.001).
Real time CCK-2 receptor proﬁle of human colonic normal
mucosa, adenoma and adenocarcinoma specimens
As real-time quantiﬁcation was to be performed, mRNA extracted
from surgically resected specimens was assessed for high integrity
by careful analysis of house-keeping gene expression. Maximal
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Figure 1 Gene expression of CCK-2 wild type (74 kDa) receptors in a panel of colonic adenoma and adenocarcinoma specimens and cell lines as de-
termined by real time PCR. Mean expression of 2 to 3 separate PCR reactions per sample are shown together with the standard deviations of the mean.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 567–573expression of a panel of house-keeping genes (glyceraldehyde phos-
phate dehydrogenase (GAPDH), Glycerol-3-phosphate dehydro-
genase (G3PDH), b-actin, 18S RNA) has previously been validated
by the use of human colonic tissue samples immediately snap-
frozen at endoscopy (D McWilliams, personal communication).
Only samples with the correct house-keeping mRNA proﬁle were
used, resulting in limited numbers for the ﬁnal assessments, as
follows: (i) non-malignant colonic mucosa (n=5), (ii) resection
margin mucosa from patients with a colonic adenocarcinoma
(n=12), (iii) villous adenomas (n=11), and (i.v.) colonic adenocar-
cinomas (n=13). The adenoma specimens expressed greater CCK-2
receptor DDCts than the adenocarcinomas (P50.0001, Mann–
Whitney), resection margin normal mucosa (P=0.0003), NIH3T3
CCK-2 receptor transfectants (P=0.005) and oxyntic mucosa
(P=0.0001). The adenocarcinomas expressed lower CCK-2 receptor
DDCt levels than oxyntic mucosa (P=0.0001) and NIH3T3 CCK-2
receptor transfectants (P=0.018), but higher levels than resection
margin mucosa (P=0.0063). Normal colonic mucosa taken from
patients without a malignancy showed no receptor expression at
the detection level of the real time PCR assay (DDCt 51610
712
for all samples examined, data not shown).
Western blot analysis of CCK-2 receptor expression of
human adenoma cell lines and colonic normal resection
margin mucosa, adenoma and adenocarcinoma specimens
Using the GRE1 antiserum, an immunoreactive band at the 74 kDa
molecular weight was expressed by the human adenoma cell lines
(Figure 2A) and the human colonic adenoma specimens (Figure
2B shows a panel of representative specimens from a series of eight
so far examined), together with normal resection margin colonic
mucosa and in one example, a synchronous adenocarcinoma. A
speciﬁc immunoreactive band was also shown at 45 kDa. The
66 kDa band was non-speciﬁc as it was also expressed in the nega-
tive control blots (epitope adsorbed antiserum).
The human colonic adenocarcinomas (a representative panel
from a series of 430 screened) all expressed an immunoreactive
doublet at both 74 and 82 kDa following staining with the GRE1
antiserum (Figure 2C). No 45 kDa band was present. The resection
margin normal mucosa expressed weaker bands, the doublet being
evident in 1 out of 3 samples shown and 74 kDa bond expressed
exclusively in 1 out of 3. The GRE1 Western blot proﬁles of the
colon adenocarcinoma cell lines have previously been published
(Watson et al, 1998). Real-time PCR conﬁrmed gene expression
of the CCK-2 receptor in selected samples (data not shown).
In vivo effect of hyper-gastrinaemia on the growth of
AA/C1/SB/10C
The mean serum amidated gastrin levels in the vehicle treated mice
(n=7/8 replicates/group) was 14.0 pM (standard deviation of 2.4)
compared to 34.0 pM in the omeprazole treated mice (standard
deviation of 10.3).
The terminal mean tumour cross-sectional areas and weights from
two separate studies are shown in Table 3. Omeprazole induced a 28%
increase in tumour area (P=0.005, Student’s t-test) and a 43% increase
in tumour weight (P=0.016). The BrdU labelling index of tumours
treated with omeprazole was assessed in the ﬁrst study only and there
was a 1.3-fold increase over vehicle treated controls (P=0.045).
CCK-2 receptor mRNA expression in the adenoma
xenografts
CCK-2 receptor mRNA was measured in adenoma xenografts from
both vehicle control and omeprazole treated mice (Table 4). There
was a 13-fold elevation in the CCK-2 receptor:GAPDH ratio in
omeprazole treated tumours (P=0.0122, Mann–Whitney).
Western blotting of the adenoma xenografts
Western blotting was performed on four xenografts from each
experimental group. Each sample was a pool of two xenografts
and each was loaded onto the gel at an equivalent protein concen-
tration. The results are shown in Figure 3. There was speciﬁc
immunoreactivity at 74, 82.5 and 120 kDa (blot shown in Figure
3a). The latter two bands were only visible in adenomas treated
with omeprazole. Densitometry scans were generated from the
Western blots and the speciﬁc bands are shown in Figure 3b.
The scans highlight the increase in density of the 74 and
82.5 kDa doublet in adenomas from omeprazole treated mice
and the novel expression of higher molecular weight immunoreac-
tivity at 120 kDa.
Reversal by blockade of the CCK-2 receptor
To conﬁrm that the in vivo growth effect was directly related to
serum hypergastrinaemia, lansoprazole was used to generate both
greater increases in serum gastrin (mean of 153.0, s.d. of 49.0 pM)
and to dissociate any molecule-speciﬁc effects of omeprazole.
GRE1 antiserum was co-administered to reverse the growth effects
by receptor blockade. Figure 4 shows that lansoprazole increased
the ﬁnal mean tumour weight by 70% (P=0.014, one way analysis
of variance). This was reversed by co-administration of GRE1
antiserum such that it was non-signiﬁcant from the vehicle
control (P=0.148 when compared to the vehicle control;
P=0.001 when compared to lansoprazole + normal rabbit serum).
GRE1 antiserum alone, signiﬁcantly reduced basal growth by 38%
(P=0.014).
Intron IV CCK-2 receptor gene expression by the
AA/C1/SB/10C adenoma cell line
Real time PCR on the above cell line conﬁrmed gene expression of
the CCK-2 receptor retaining intron IV. The mean DDCt of two
separate cDNA samples performed twice was 0.021 (standard
deviation of 0.014) indicating positive expression.
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Table 4 Effect of omeprazole treatment on the CCK-2 recep-
tor:GAPDH mRNA expression of AA/C1/5B/10C xenografts
CCK-2 receptor:GAPDH ratio
Treatment group Median (95% conﬁdence interval)
Vehicle control 0.03 (0.01–0.10)
Omeprazole 0.40 (0.21–0.57)
a
aP=0.0122, Mann–Whitney.
Table 3 Effect of omeprazole-induced hyper-gastrinaemia on the in vivo
growth of the human transformed colonic adenoma AA/C1/10B/SC as
assessed by tumour cross-sectional area, tumour weight measurement
and labelling index
Labelling index
Group Mean tumour %BrdU +ve
(n=15 cross-sectional Mean tumour nuclei/total tissue
mice/group) area (mm
2) weight (g) area
Vehicle 128.15 (38.55) 0.37 (0.12) 7.1 (0.6)
Omeprazole 164.15 (44.47) 0.53 (0.15) 9.3 (1.9)
Two separate studies
a P=0.005
a P=0.016
a P=0.045
(1st study only)
aSigniﬁcantly increased when compared to the vehicle control, Student’s t-test.
(Standard deviations are shown in brackets).
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Serum hypergastrinaemia has become a more common occurrence
in recent years, partly as a result of an increase in the use of
proton pump inhibitors for acid secretory disorders (Festen et
al, 1986; Lind et al, 1988). Furthermore, a positive temporal rela-
tionship has been observed between hyper-gastrinaemia and
increased incidence of colon cancer with 8.9% of colon cancer
being shown to be attributable to elevated gastrin levels (Thor-
burn et al, 1998), indicating a sub-group of patients exhibiting
increased sensitivity.
Recent publications have indicated that for serum hyper-gastri-
naemia to impact upon tumour progression there needs to be co-
expression of CCK-2 receptors. In transgenic mouse models of
hypergastrinaemia, gastrin induces CCK-2 receptor expression in
gastric pit cell precursors (Nakajima et al, 2002) and invasive
gastric carcinoma (Wang and Dockray, 1999). To induce pancrea-
tic carcinomas, the hyper-gastrinaemic hGAS transgenic mouse
model was crossed with the ELAS CCK-2 receptor mouse which
over-expresses CCK-2 receptors in the pancreas. In 13% of the
hybrid mice, carcinoma of the pancreas was present by 18 months
(Clerc et al, 2002).
Studies determining the effect of hyper-gastrinaemia on pre-
malignant polyps in the human colon have been limited despite
it being shown that CCK-2 receptors are expressed by human
adenomas (Smith and Watson, 2000). The incidence of colonic
polyps was reported to be increased in patients with Helicobacter
pylori infection (Breuer-Katschinski et al, 1999) but any relation-
ship between serum hyper-gastrinaemia and adenoma/polyp
proliferation remains tenuous. In the present study, maximal
expression of classical CCK-2 receptor gene was shown in both
human colonic adenoma cell lines and human adenoma speci-
mens when compared to colonic adenocarcinomas. This is the
ﬁrst study to indicate that the proliferative effects of serum
hyper-gastrinaemia on tumour progression may have maximum
impact during the adenoma stage. It may also explain the sensi-
tivity of the APC
Min mouse to elevated gastrin levels, which
resulted in decreased survival (Watson and Smith, 2001). The
8.9% colorectal cancers arising from serum hyper-gastrinaemia
may therefore represent a population of patients with pre-existing
colonic polyps.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
A
Specific
band
at 74 kDa
AA/C1/5B/10C AA/C1 RGC2/42
66
45
GRE1 antiserum treated Epitope-adsorbed GRE1
antiserum
GRE1
antiserum
treated
Epitope-
adsorbed
GRE1
antiserum
NACNANANA
116
66
45
29
116
66
45
29
Specific band
at 74 kDa
Specific band
at 45 kDa
B
Specific band
at 82kDa
and  74 kDa GRE1
antiserum
treated
Epitope-
adsorbed
GRE1
antiserum
NCN CNC
66
45
66
45
C
MWt Markers
(kDa)
MWt Markers
(kDa)
Figure 2 Western blot analysis showing CCK-2 receptor isoform immu-
no-reactivity of human colonic adenoma specimens and human colonic
adenoma cell lines. (A) Human colonic adenoma cell lines. (B) Human co-
lonic adenoma specimens. Resection margin normal (N), adenoma (A) and
adenocarcinoma (C) specimens from individual patients. (C) Human colo-
nic adenocarcinoma specimens. Resection margin normal (N) and adeno-
carcinoma (C) specimens from individual patients.
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Figure 3 Western blot analysis showing CCK-2 receptor immuno-reac-
tivity of human colonic adenoma xenografts. (A) Western blots (+ome-
prazole treatment). (B) Densitometry scans of the immunoreactive
bands generated from the Western blots. Red line: imunoreactive bands
from grafts obtained from omeprazole-treated mice. Blue line: immuno-
reactive bands from grafts obtained from vehicle-treated mice.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 567–573The reason for the lower gene expression of the classical CCK-2
receptor at the adenocarcinoma stage is unknown. At the protein
level we have previously shown that the intron IV retained CCK-
2 receptor splice variant may be the predominant form expressed
by colonic adenocarcinomas (Clarke et al, 1999; 2001). In the
present study, an 82 kDa immuno-reactive band was co-expressed
with the 74 kDa band (relating to the molecular weight of the clas-
sical CCK-2 receptor) following Western blotting with a CCK-2
receptor antiserum in a series of human colonic adenocarcinomas.
The larger molecular weight isoform of the CCK-2 receptor was
absent from a panel of human adenomas. The 82 kDa band relates
(in terms of molecular weight) to the intron IV CCK-2 receptor
isoform that would be detected by the antiserum as it is directed
against the amino-terminal domain common to both CCK-2 recep-
tor isoforms.
The primers used in the real time PCR method were designed
for optimal detection of classical CCK-2 receptor and would
detect the intron IV containing receptor much less efﬁciently.
Thus, the variations in CCK-2 receptor gene expression between
adenomas and adenocarcinomas could reﬂect a shift to greater
expression of intron IV retained CCK-2 receptor isoforms in
adenocarcinomas.
Alternatively, it is known that gastrin gene expression is greater
in colonic adenocarcinomas than in adenomas (Watson et al,
1999b) and in a series of GI cell lines transfected to over-express
the gastrin gene, there was down-regulation of gene and protein
expression of classical CCK-2, but not Intron IV CCK-2, receptor
isoforms (S Evans, personal communication). Therefore, increased
gastrin gene expression could be partly responsible for the down-
regulation in CCK-2 receptor gene expression seen in the adeno-
carcinomas. Expression of CCK-2 receptors by human colonic
adenomas suggests that the cells may be responsive to serum
hyper-gastrinaemia. The CCK-2 receptors expressed by AA/C1/
1B/5B were shown to be functional, as following in vivo growth,
the receptors were up-regulated at both the gene and protein level
and mediated a growth response to increased serum gastrin levels
induced by administration of protein pump inhibitors. The signif-
icant but modest increase in BrdU uptake in omeprazole treated
mice may reﬂect the poorly vascularised status of the subcutaneous
grafts at the end-stage of the study. Tumour growth in the lanso-
prazole treated mice was greater than in the omeprazole treated
mice, which may relate to the higher serum gastrin levels, and
was completely reversed by co-administration of antiserum block-
ading the CCK-2 receptor, conﬁrming the growth effect as
gastrin-speciﬁc.
Interestingly, following growth in hyper-gastrinaemic mice, de
novo expression of the 82 kDa form of the CCK-2 receptor was
conﬁrmed in AA/C1/SB/10C grafts. This may indicate a shift to a
more malignant phenotype in the present adenoma model follow-
ing exposure to gastrin. Furthermore, a CCK-2 receptor isoform of
molecular weight 120 kDa was exclusively expressed in adenoma
grafts from hyper-gastrinaemic mice, the structure/function of
which has so far not been described.
Thus further clinical studies are warranted to examine the
proliferation of polyps from patients with elevated levels of serum
gastrin. It may be that the 8.9% of total colorectal cancers that are
attributable to serum gastrin levels may arise in patients with
undiagnosed colonic polyps, due to the increased expression of
CCK-2 receptors on these pre-malignant lesions. Carefully
controlled epidemiological studies are necessary to relate hyper-
gastrinaemia to the incidence of colorectal cancer, considering
the widespread use of protein pump inhibitors.
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